Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 1

Conditions

Lung Neoplasms 2Urinary Bladder Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 304Carboplatin 155Nivolumab 155Cisplatin 140Cyclophosphamide 132Paclitaxel 128Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 91Gemcitabine 87Dexamethasone 85Biopsy 81Ipilimumab 78Doxorubicin 76Docetaxel 75Rituximab 70Etoposide 67atezolizumab 62durvalumab 61Radiation 60Lenalidomide 59Pemetrexed 58Taxes 57Bevacizumab 55Prednisone 55fludarabine 54olaparib 54Vincristine 50Cytarabine 48Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × NPI 2358 × 1 year × Clear all
NCT02504489 2026-05-19

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
559 enrolled 32 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

M.D. Anderson Cancer Center

Phase 1/2 Terminated
19 enrolled 11 charts
GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Big Ten Cancer Research Consortium

Phase 1/2 Completed
39 enrolled 18 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡